Piper Sandler analyst Matt O’Brien raised the firm’s price target on CVRx to $18.50 from $14 and keeps an Overweight rating on the shares. The company’s preannounced Q4 sales beat Piper’s estimate but its sales guidance for fiscal 2023 came in below expectations, O’Brien tells investors in a research note. However, CVRx’s margins are expected to come in better than estimates, says the analyst, who continues to see "meaningful value creation ahead" for the company.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVRX:
- CVRx sees FY23 revenue $35M-$38M, consensus $38M
- CVRx sees FY22 revenue $22.3M-$22.4M, consensus $22.16M
- CVRx sees Q4 revenue $7M-$7.1M, consensus $6.92M
- CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
- CVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference